Literature DB >> 11587143

Dry eye disease: the scale of the problem.

H Brewitt1, F Sistani.   

Abstract

Dry eye disease, or keratoconjunctivitis sicca, is among the most frequently established diagnoses in ophthalmology; in Germany, one in four patients consulting an ophthalmologist complains of the symptoms of dry eye. Although epidemiological studies investigating the prevalence of dry eye disease are rare, published studies indicate that up to 20% of adults aged 45 years or more experience dry eye symptoms. Recent studies have shown that immunologic changes play a role in the pathogenesis of dry eye, not only in Sjögren's syndrome, but also in postinfectious and age-related conditions. Despite increasing understanding of the pathogenic factors involved in dry eye disease, there has been a lack of consensus on diagnostic criteria, classification of disease states, and the aims and interpretation of specific diagnostic tests. There is a need, therefore, for standardization of disease terminology and diagnostic tests in order to improve the usefulness of epidemiological and clinical investigation of this important ocular disorder.

Entities:  

Mesh:

Year:  2001        PMID: 11587143     DOI: 10.1016/s0039-6257(00)00202-2

Source DB:  PubMed          Journal:  Surv Ophthalmol        ISSN: 0039-6257            Impact factor:   6.048


  58 in total

1.  Tear film status in patients attending the eye clinic in South sharqiya region.

Authors:  Belur R Keshav; Biju Mathews; Mary Joseph; George Zachariah; Thara Ideculla
Journal:  Oman Med J       Date:  2007-10

2.  Ocular manifestations of trichothiodystrophy.

Authors:  Brian P Brooks; Amy H Thompson; Janine A Clayton; Chi-Chao Chan; Deborah Tamura; Wadih M Zein; Delphine Blain; Casey Hadsall; John Rowan; Kristen E Bowles; Sikandar G Khan; Takahiro Ueda; Jennifer Boyle; Kyu-Seon Oh; John J DiGiovanna; Kenneth H Kraemer
Journal:  Ophthalmology       Date:  2011-09-28       Impact factor: 12.079

3.  Iodide iontophoresis as a treatment for dry eye syndrome.

Authors:  J Horwath-Winter; O Schmut; E-M Haller-Schober; A Gruber; G Rieger
Journal:  Br J Ophthalmol       Date:  2005-01       Impact factor: 4.638

4.  Prevalence of dry eye in video display terminal users: a cross-sectional Caucasian study in Italy.

Authors:  Gemma Caterina Maria Rossi; Luigia Scudeller; Federica Bettio; Gian Maria Pasinetti; Paolo Emilio Bianchi
Journal:  Int Ophthalmol       Date:  2018-06-07       Impact factor: 2.031

Review 5.  Modern Therapeutic Approaches for Noninfectious Ocular Diseases Involving Inflammation.

Authors:  Michelle L Ratay; Elena Bellotti; Riccardo Gottardi; Steven R Little
Journal:  Adv Healthc Mater       Date:  2017-10-16       Impact factor: 9.933

6.  Accelerated Restoration of Ocular Surface Health in Dry Eye Disease by Self-Retained Cryopreserved Amniotic Membrane.

Authors:  Anny M S Cheng; Dandan Zhao; Rendian Chen; Han Y Yin; Sean Tighe; Hosam Sheha; Victoria Casas; Scheffer C G Tseng
Journal:  Ocul Surf       Date:  2015-09-24       Impact factor: 5.033

7.  The effect of pH, dilution, and temperature on the viscosity of ocular lubricants--shift in rheological parameters and potential clinical significance.

Authors:  M Q Rahman; K-S Chuah; E C A Macdonald; J P M Trusler; K Ramaesh
Journal:  Eye (Lond)       Date:  2012-10-19       Impact factor: 3.775

8.  [Meibomian glands : part III. Dysfunction - argument for a discrete disease entity and as an important cause of dry eye].

Authors:  E Knop; N Knop; H Brewitt; U Pleyer; P Rieck; B Seitz; F Schirra
Journal:  Ophthalmologe       Date:  2009-11       Impact factor: 1.059

9.  The role of omega-3 dietary supplementation in blepharitis and meibomian gland dysfunction (an AOS thesis).

Authors:  Marian S Macsai
Journal:  Trans Am Ophthalmol Soc       Date:  2008

10.  Osmoprotective effects of supplemental epidermal growth factor in an ex vivo multilayered human conjunctival model under hyperosmotic stress.

Authors:  Jae-hyung Kim; Soon-Suk Kang; Eun Soon Kim; Jae Yong Kim; Myoung Joon Kim; Hungwon Tchah
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-05-16       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.